1 / 1

ATLAS ACS-TIMI 46

ATLAS ACS-TIMI 46. No difference between rivaroxaban and placebo in the primary outcome (death, MI, stroke, severe ischemia) ( HR 0.79, 95% CI 0.60-1.05) ↓ in death, MI, stroke with rivaroxaban

aysha
Télécharger la présentation

ATLAS ACS-TIMI 46

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ATLAS ACS-TIMI 46 No difference between rivaroxaban and placebo in the primary outcome (death, MI, stroke, severe ischemia) (HR 0.79, 95% CI 0.60-1.05) ↓ in death, MI, stroke with rivaroxaban Dose-response curve for bleeding with rivaroxaban, especially in the setting of dual antiplatelet therapy (p < 0.001) (p = 0.10) (p = 0.028) Placebo (n = 1,160) Rivaroxaban (n = 1,166) Trial design: Patients with ACS were randomized to either rivaroxaban twice daily, once daily, or placebo. Clinical outcomes were compared at 6 months. Results 20 20 15 15 % % 10 10 7.0 Conclusions 5.6 5.5 • Rivaroxaban has reasonable efficacy compared with placebo in patients with ACS, with a higher bleeding risk • This was a phase II clinical trial conducted to identify safe and effective doses of rivaroxaban to be used in the phase III trial 5 3.9 5 0 0 Primary outcome Death/MI/Stroke Mega JL, et al. Lancet 2009;Jun 17:Epub

More Related